Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutic (NQ: HALO )

51.16 +0.31 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,183,854
Open 49.27
Bid (Size) 50.50 (1)
Ask (Size) 54.99 (1)
Prev. Close 50.85
Today's Range 49.17 - 51.66
52wk Range 32.83 - 53.00
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Novavax And Agios Pharmaceuticals Were Among The 10 Biggest Mid-Cap Gainers Last Week (June 1-June 7): Are These In Your Portfolio?
Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their forecasts. 
Via Benzinga
Halozyme Therapeutics Scores RS Rating Jump To 91
On Friday, Halozyme Therapeutics stock earned an upgrade to its Relative Strength (RS) Rating, from 80 to 91. 
Via Investor's Business Daily

Performance

YTD
+36.83%
+36.83%
1 Month
+17.31%
+17.31%
3 Month
+24.17%
+24.17%
6 Month
+26.32%
+26.32%
1 Year
+49.81%
+49.81%

More News

Read More
This Exxon Mobil Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Via Benzinga
Halozyme Therapeutics +13% On Thursday: What's Going On?
Via Benzinga
Topics Intellectual Property
Exposures Intellectual Property
J.M. SmuckerPosts Upbeat Earnings, Joins Toro Company, United Natural Foods, Semtech And Other Big Stocks Moving Higher On Thursday
Via Benzinga
NASDAQ:HALO, a growth stock which is not overvalued.
Via Chartmill
Why G-III Apparel Shares Are Trading Lower By 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
A Glimpse Into The Expert Outlook On Halozyme Therapeutics Through 8 Analysts
Via Benzinga
NASDAQ:HALO is probably undervalued for the fundamentals it is displaying.
Via Chartmill
While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable.
Via Chartmill
Expert Ratings For Halozyme Therapeutics
Via Benzinga
Exploring the Growth Potential of NASDAQ:HALO as It Nears a Breakout.
Via Chartmill
Halozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Catalyst Pharmaceuticals Stock Clears Technical Benchmark With 83 RS Rating
Via Investor's Business Daily
The 3 Best Biotech Stocks to Buy in May 2024
Via InvestorPlace
When you look at NASDAQ:HALO, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
HALO Stock Earnings: Halozyme Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
Via Investor's Business Daily
NASDAQ:HALO is not too expensive for the growth it is showing.
Via Chartmill
9 Analysts Have This To Say About Halozyme Therapeutics
Via Benzinga
NASDAQ:HALO—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
Sarepta Therapeutics Stock Shows Improved Technical Strength
Via Investor's Business Daily
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Via InvestorPlace
Investors should take notice of NASDAQ:HALO—it offers a great deal for the fundamentals it presents.
Via Chartmill
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.